Eli Lilly Gross Margin 1986-2025 | LLY

Current and historical gross margin for Eli Lilly (LLY) over the last 10 years. The current gross profit margin for Eli Lilly as of June 30, 2025 is %.
Eli Lilly Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2025-06-30 $53.26B $44.01B 82.64%
2025-03-31 $49.00B $40.03B 81.70%
2024-12-31 $45.04B $36.63B 81.31%
2024-09-30 $40.86B $33.06B 80.91%
2024-06-30 $38.92B $31.43B 80.75%
2024-03-31 $35.93B $28.80B 80.16%
2023-12-31 $34.12B $27.04B 79.25%
2023-09-30 $32.07B $25.23B 78.67%
2023-06-30 $29.52B $22.96B 77.77%
2023-03-31 $27.69B $21.51B 77.67%
2022-12-31 $28.54B $21.91B 76.77%
2022-09-30 $29.24B $22.11B 75.61%
2022-06-30 $29.07B $22.09B 75.98%
2022-03-31 $29.32B $21.82B 74.40%
2021-12-31 $28.32B $21.01B 74.18%
2021-09-30 $27.76B $20.78B 74.84%
2021-06-30 $26.73B $19.85B 74.26%
2021-03-31 $25.49B $19.34B 75.88%
2020-12-31 $24.54B $19.06B 77.65%
2020-09-30 $23.21B $18.17B 78.26%
2020-06-30 $22.95B $18.06B 78.67%
2020-03-31 $23.09B $18.29B 79.22%
2019-12-31 $22.32B $17.60B 78.85%
2019-09-30 $21.84B $17.28B 79.09%
2019-06-30 $21.67B $17.13B 79.03%
2019-03-31 $21.62B $16.97B 78.47%
2018-12-31 $21.49B $16.81B 78.22%
2018-09-30 $19.12B $15.63B 81.72%
2018-06-30 $19.47B $15.54B 79.83%
2018-03-31 $19.71B $15.45B 78.37%
2017-12-31 $19.97B $15.53B 77.73%
2017-09-30 $22.47B $16.44B 73.18%
2017-06-30 $22.01B $16.16B 73.45%
2017-03-31 $21.59B $15.85B 73.43%
2016-12-31 $21.22B $15.51B 73.09%
2016-09-30 $20.84B $15.26B 73.23%
2016-06-30 $20.61B $15.19B 73.72%
2016-03-31 $20.18B $15.01B 74.39%
2015-12-31 $19.96B $14.92B 74.75%
2015-09-30 $19.71B $14.80B 75.12%
2015-06-30 $19.62B $14.69B 74.86%
2015-03-31 $19.58B $14.68B 74.96%
2014-12-31 $19.62B $14.68B 74.85%
2014-09-30 $20.30B $15.24B 75.04%
2014-06-30 $21.20B $16.20B 76.43%
2014-03-31 $22.20B $17.22B 77.59%
2013-12-31 $23.11B $18.21B 78.77%
2013-09-30 $23.26B $18.49B 79.50%
2013-06-30 $22.93B $18.16B 79.18%
2013-03-31 $22.60B $17.85B 78.96%
2012-12-31 $22.60B $17.81B 78.78%
2012-09-30 $22.69B $17.82B 78.54%
2012-06-30 $23.40B $18.39B 78.61%
2012-03-31 $24.05B $18.96B 78.85%
2011-12-31 $24.29B $19.22B 79.13%
2011-09-30 $24.43B $19.45B 79.62%
2011-06-30 $23.93B $19.31B 80.66%
2011-03-31 $23.43B $19.01B 81.12%
2010-12-31 $23.08B $18.71B 81.08%
2010-09-30 $22.82B $18.26B 79.99%
2010-06-30 $22.73B $18.10B 79.63%
2010-03-31 $22.28B $17.72B 79.56%
2009-12-31 $21.84B $17.59B 80.55%
2009-09-30 $21.11B $17.38B 82.35%
2009-06-30 $20.75B $16.93B 81.55%
2009-03-31 $20.61B $16.53B 80.20%
2008-12-31 $20.37B $16.00B 78.51%
2008-09-30 $20.36B $15.62B 76.71%
2008-06-30 $19.74B $15.10B 76.49%
2008-03-31 $19.22B $14.78B 76.90%
2007-12-31 $18.63B $14.39B 77.20%
2007-09-30 $17.69B $13.69B 77.42%
2007-06-30 $16.97B $13.17B 77.60%
2007-03-31 $16.20B $12.54B 77.40%
2006-12-31 $15.69B $12.14B 77.39%
2006-09-30 $15.33B $11.90B 77.64%
2006-06-30 $15.06B $11.65B 77.35%
2006-03-31 $14.86B $11.44B 76.97%
2005-12-31 $14.65B $11.17B 76.27%
2005-09-30 $14.41B $10.97B 76.11%
2005-06-30 $14.09B $10.68B 75.83%
2005-03-31 $13.98B $10.65B 76.18%
2004-12-31 $13.86B $10.63B 76.74%
2004-09-30 $13.68B $10.59B 77.41%
2004-06-30 $13.54B $10.58B 78.14%
2004-03-31 $13.07B $10.26B 78.53%
2003-12-31 $12.58B $9.91B 78.74%
2003-09-30 $12.07B $9.56B 79.20%
2003-06-30 $11.72B $9.33B 79.64%
2003-03-31 $11.41B $9.14B 80.12%
2002-12-31 $11.08B $8.90B 80.35%
2002-09-30 $10.95B $8.78B 80.13%
2002-06-30 $11.04B $8.87B 80.33%
2002-03-31 $11.30B $9.13B 80.80%
2001-12-31 $11.54B $9.38B 81.27%
2001-09-30 $11.69B $9.53B 81.52%
2001-06-30 $11.63B $9.53B 81.93%
2001-03-31 $11.22B $9.15B 81.55%
2000-12-31 $10.86B $8.81B 81.07%
2000-09-30 $10.71B $8.65B 80.79%
2000-06-30 $10.48B $8.36B 79.82%
2000-03-31 $10.20B $8.09B 79.27%
1999-12-31 $10.00B $7.91B 79.02%
1999-09-30 $9.82B $8.17B 83.17%
1999-06-30 $9.81B $8.04B 81.94%
1999-03-31 $9.81B $7.90B 80.56%
1998-12-31 $9.82B $7.80B 79.49%
1998-09-30 $9.44B $6.86B 72.67%
1998-06-30 $9.03B $6.53B 72.30%
1998-03-31 $8.69B $6.26B 72.09%
1997-12-31 $8.37B $6.01B 71.77%
1997-09-30 $8.17B $5.90B 72.23%
1997-06-30 $7.82B $5.63B 72.05%
1997-03-31 $7.52B $5.38B 71.51%
1996-12-31 $7.35B $5.23B 71.17%
1996-09-30 $7.09B $5.07B 71.49%
1996-06-30 $6.91B $4.98B 71.98%
1996-03-31 $6.83B $4.94B 72.30%
1995-12-31 $6.76B $4.88B 72.12%
1995-09-30 $6.51B $4.66B 71.56%
1995-06-30 $6.39B $4.50B 70.52%
1995-03-31 $6.45B $4.64B 71.96%
1994-12-31 $6.04B $4.36B 72.22%
1994-09-30 $6.30B $4.50B 71.49%
1994-06-30 $6.32B $4.51B 71.33%
1994-03-31 $6.20B $4.31B 69.45%
1993-12-31 $6.45B $4.49B 69.63%
1993-09-30 $6.31B $4.44B 70.40%
1993-06-30 $6.25B $4.32B 69.10%
1993-03-31 $6.17B $4.26B 69.08%
1992-12-31 $6.17B $4.27B 69.26%
1992-09-30 $6.09B $4.12B 67.77%
1992-06-30 $5.95B $4.13B 69.41%
1992-03-31 $5.85B $4.08B 69.85%
1991-12-31 $5.73B $4.01B 70.00%
1991-09-30 $5.60B $3.93B 70.20%
1991-06-30 $5.54B $3.88B 70.12%
1991-03-31 $5.39B $3.75B 69.69%
1990-12-31 $5.19B $3.61B 69.43%
1990-09-30 $4.53B $3.27B 72.24%
1990-06-30 $4.30B $3.08B 71.64%
1990-03-31 $4.19B $2.98B 71.04%
1989-12-31 $4.18B $2.92B 69.90%
1989-09-30 $3.97B $2.77B 69.74%
1989-06-30 $3.87B $2.69B 69.54%
1989-03-31 $3.76B $2.60B 69.18%
1988-12-31 $3.61B $2.48B 68.82%
1988-09-30 $3.64B $2.39B 65.72%
1988-06-30 $3.66B $2.39B 65.36%
1988-03-31 $3.66B $2.37B 64.84%
1987-12-31 $3.65B $2.34B 64.22%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $495.141B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12